🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07790224
Starting soon Not applicable

Multi-Parameter Temporal Interference Stimulation in Patients With Epilepsy Undergoing SEEG Monitoring

NCT07790224 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Sanbo Brain Hospital
Phase
Not applicable
Started
2026-08-30
Last updated
2026-08-27

Condition(s) studied

Epilepsy

Investigational drug(s) / intervention(s)

Temporal Interference Stimulation

Temporal Interference Stimulation: Participants will receive individualized temporal interference (TI) stimulation targeting one or two deep brain regions selected according to SEEG electrode coverage and individual neuroimaging data. Scalp electrode placement and stimulation intensity will be optimized using individualized finite-element modeling. Multiple beat-frequency conditions corresponding to delta, theta, alpha, beta, gamma, and high-gamma frequency ranges will be administered in randomized order. SEEG activity will be recorded before, during, and after stimulation.

Study summary

This prospective exploratory interventional study aims to investigate the neurophysiological effects and safety of multi-parameter temporal interference (TI) stimulation in patients undergoing stereoelectroencephalography (SEEG) monitoring. Participants who have already undergone SEEG electrode implantation for clinical indications will receive non-invasive TI stimulation targeting selected deep brain regions according to their individual electrode coverage and neuroimaging data. Multiple stimulation frequencies will be tested while intracranial SEEG signals are recorded before, during, and after stimulation. The study will characterize frequency-dependent changes in local and distributed brain activity and explore the relationship between TI stimulation parameters and neurophysiological responses, providing in vivo evidence for parameter optimization of non-invasive deep brain stimulation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 18 to 70 years, inclusive, with no restriction on sex. * Has undergone stereoelectroencephalography (SEEG) electrode implantation, with electrode contacts covering the target deep brain region(s), such as the thalamus, hippocampus, amygdala, or cingulate cortex. * Is in the postoperative SEEG monitoring period, is clinically stable, and is able to comply with the study procedures. * The participant or the participant's legally authorized representative is able to fully understand the purpose and procedures of the study and voluntarily provides written informed consent. Exclusion Criteria: * Contraindications to magnetic resonance imaging (MRI), such as incompatible metallic implants or a cardiac pacemaker. * Psychiatric disorders or severe cognitive impairment. * Structural brain abnormalities, such as cerebral infarction, hydrocephalus, or severe thalamic atrophy. * Other severe neurological disorders that may interfere with participation in the study. * Medical or psychiatric contraindications, including recent myocardial infarction, cardiac arrhythmia, stroke, autonomic dysfunction, endocrine disorders, uncontrolled or difficult-to-control hypertension or hypotension, deep brain stimulation for other reasons, degenerative central nervous system disorders, or severe electrolyte disturbances. * Pregnancy or breastfeeding. * Participation in another drug or medical device clinical study within 3 months before screening. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Sanbo Brain Hospital Beijing Beijing Municipality

More Beijing Sanbo Brain Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07790224 on ClinicalTrials.gov ↗ ← All trials in China